AP2011005774A0 - Glucagon analogues. - Google Patents

Glucagon analogues.

Info

Publication number: AP2011005774A0
Authority: AP; ARIPO
Prior art keywords: glucagon analogues; glucagon; analogues
Prior art date: 2008-12-15

Application number

AP2011005774A

Other languages

English (en)

Inventor

Jens Rosengren Daugaard

Eddi Meier

Ditte Riber

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-15

Filing date

2008-12-15

Publication date

2011-06-30

2008-12-15 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2008-12-15 Priority to AP2011005774A priority Critical patent/AP2011005774A0/xx

2011-06-30 Publication of AP2011005774A0 publication Critical patent/AP2011005774A0/xx

Links

MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Microbiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)

AP2011005774A 2008-12-15 2008-12-15 Glucagon analogues. AP2011005774A0 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AP2011005774A AP2011005774A0 (en)	2008-12-15	2008-12-15	Glucagon analogues.

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/GB2008/004121 WO2010070251A1 (fr)	2008-12-15	2008-12-15	Analogues du glucagon
AP2011005774A AP2011005774A0 (en)	2008-12-15	2008-12-15	Glucagon analogues.

Publications (1)

Publication Number	Publication Date
AP2011005774A0 true AP2011005774A0 (en)	2011-06-30

Family

ID=40428061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2011005774A AP2011005774A0 (en)	2008-12-15	2008-12-15	Glucagon analogues.

Country Status (19)

Country	Link
US (2)	US8685919B2 (fr)
EP (2)	EP2799447B1 (fr)
JP (1)	JP5635529B2 (fr)
KR (2)	KR20150116912A (fr)
CN (1)	CN102282167B (fr)
AP (1)	AP2011005774A0 (fr)
AU (1)	AU2008365555B2 (fr)
BR (1)	BRPI0823378A2 (fr)
CA (1)	CA2747109A1 (fr)
EA (1)	EA020537B1 (fr)
HK (1)	HK1203531A1 (fr)
IL (1)	IL213477A0 (fr)
MA (1)	MA32970B1 (fr)
MX (1)	MX2011006313A (fr)
MY (1)	MY160219A (fr)
SG (1)	SG172170A1 (fr)
TN (1)	TN2011000295A1 (fr)
UA (1)	UA104605C2 (fr)
WO (1)	WO2010070251A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101171262B (zh)	2005-05-04	2012-06-27	西兰制药公司	胰高血糖素样肽-2(glp-2)类似物
NZ576260A (en)	2006-11-08	2012-04-27	Zealand Pharma As	GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
US8680049B2 (en)	2008-12-15	2014-03-25	Zealand Pharma A/S	Glucagon analogues
JP5635530B2 (ja)	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
ES2439499T3 (es)	2008-12-15	2014-01-23	Zealand Pharma A/S	Análogos de glucagón
PT2454282E (pt) *	2009-07-13	2015-06-23	Zealand Pharma As	Análogos de glucagão acilados
BR112012027759A2 (pt)	2010-04-27	2017-08-15	Zealand Pharma As	Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
MA34383B1 (fr)	2010-06-24	2013-07-03	Zealand Pharma As	Analogues de glucagon
MX2013008005A (es) *	2011-01-20	2013-08-21	Zealand Pharma As	Combinacion de analogos de glucagon acilados con analogos de insulina.
WO2013041678A1 (fr) *	2011-09-23	2013-03-28	Novo Nordisk A/S	Nouveaux analogues du glucagon
AU2012331053A1 (en)	2011-11-03	2014-05-29	Zealand Pharma A/S	GLP-1 receptor agonist peptide gastrin conjugates
AR090937A1 (es)	2012-05-03	2014-12-17	Zealand Pharma As	Compuestos agonista duales de gip-glp-1 y metodos para usarlos
CN104540850B (zh)	2012-05-03	2018-05-18	西兰制药公司	胰高血糖素样肽2(glp-2)类似物
EP2664374A1 (fr) *	2012-05-15	2013-11-20	F. Hoffmann-La Roche AG	Dérivés de dipeptide d'acide lysine-glutamique
AR091422A1 (es)	2012-06-14	2015-02-04	Sanofi Sa	Analogos peptidicos de la exendina 4
BR112015001451B1 (pt)	2012-07-23	2022-03-29	Zealand Pharma A/S	Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
AR092873A1 (es)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PT2934568T (pt)	2012-12-21	2018-01-04	Sanofi Sa	Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
HK1219477A1 (zh)	2013-03-21	2017-04-07	Sanofi-Aventis Deutschland Gmbh	合成含有乙内酰脲的肽产物
SG11201506885UA (en)	2013-03-21	2015-09-29	Sanofi Aventis Deutschland	Synthesis of cyclic imide containing peptide products
WO2014161835A1 (fr)	2013-04-03	2014-10-09	Sanofi	Protéines de régulation de la glycémie modifiées ayant un profil d'activité pharmacologique modifié, et leur préparation
RU2683039C2 (ru)	2013-04-18	2019-03-26	Ново Нордиск А/С	Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
US9988429B2 (en) *	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
MX368436B (es)	2013-10-17	2019-10-03	Zealand Pharma As	Analogos de glucagon acilados.
CA2929459C (fr) *	2013-11-06	2022-05-03	Zealand Pharma A/S	Composes agonistes doubles de gip et glp-1 et procedes associes
KR102310392B1 (ko)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086731A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine-4 en tant qu'agonistes mixtes des récepteurs glp-1/glucagon
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
JP2017525656A (ja)	2014-06-04	2017-09-07	ノヴォノルディスクアー／エス	医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
ES2883345T3 (es)	2014-10-29	2021-12-07	Zealand Pharma As	Compuestos agonistas del GIP y métodos
PT3258919T (pt)	2015-02-17	2020-03-26	Lilly Co Eli	Formulação em pó nasal para tratamento da hipoglicemia
TWI748945B (zh) *	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
AR103954A1 (es)	2015-03-18	2017-06-14	Zealand Pharma As	Análogos de amilina
WO2016168388A2 (fr)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Thérapies pour l'obésité, le diabète et indications associées
PL3283507T3 (pl)	2015-04-16	2020-05-18	Zealand Pharma A/S	Acylowany analog glukagonu
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (fr)	2015-06-12	2016-12-15	Sanofi	Dérivés d'exendine-4 non-acylée comme agonistes doubles du récepteur glp -1/glucagon
WO2016198624A1 (fr)	2015-06-12	2016-12-15	Sanofi	Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
LT3494120T (lt)	2016-08-05	2021-05-25	Boehringer Ingelheim International Gmbh	Oksadiazolopiridino dariniai, skirti naudoti kaip grelino o-aciltransferazės (goat) inhibitoriai
TWI784968B (zh)	2016-09-09	2022-12-01	丹麥商西蘭製藥公司	澱粉素類似物
TW201832783A (zh)	2016-12-02	2018-09-16	法商賽諾菲公司	包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
CA3043151A1 (fr)	2016-12-09	2018-06-14	Zealand Pharma A/S	Agonistes doubles de glp-1/glp-2 acyles
WO2018103868A1 (fr) *	2016-12-09	2018-06-14	Zealand Pharma A/S	Agonistes doubles de glp-1/glp-2 acylés
EP4424362A3 (fr)	2017-06-16	2024-11-27	Zealand Pharma A/S	Régimes posologiques pour l'administration d'analogues de peptide-2 de type glucagon (glp-2)
CN111655700B (zh)	2018-02-02	2023-07-18	勃林格殷格翰国际有限公司	作为饥饿素o-酰基转移酶(goat)抑制剂的噁二唑并吡啶衍生物
EP3746443B1 (fr)	2018-02-02	2022-07-06	Boehringer Ingelheim International GmbH	Dérivés de triazolopyrimidine destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
WO2019149659A1 (fr)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
CN111630055B (zh)	2018-02-02	2023-07-14	勃林格殷格翰国际有限公司	用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物
WO2019197466A1 (fr) *	2018-04-10	2019-10-17	Sanofi-Aventis Deutschland Gmbh	Procédé de clivage de peptides liés à une phase solide à partir de la phase solide
CN115947849A (zh)	2018-12-21	2023-04-11	江苏恒瑞医药股份有限公司	双特异性蛋白
TWI771669B (zh)	2019-04-26	2022-07-21	美商美國禮來大藥廠	製備穩定胜肽調配物之方法
MX2022005661A (es)	2019-11-11	2022-09-07	Boehringer Ingelheim Int	Agonistas del receptor npy2.
WO2022029231A1 (fr)	2020-08-07	2022-02-10	Boehringer Ingelheim International Gmbh	Agonistes du récepteur npy2 solubles

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ202757A (en)	1981-12-23	1985-11-08	Novo Industri As	Peptides and medicaments
ES2283025T3 (es)	1996-08-30	2007-10-16	Novo Nordisk A/S	Derivados de glp-1.1.
ATE290014T1 (de)	1996-09-09	2005-03-15	Zealand Pharma As	Festphasen-peptidsynthese
CA2265454A1 (fr)	1996-09-09	1998-03-19	Zealand Pharmaceuticals A/S	Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide
NZ504258A (en)	1997-11-14	2002-12-20	Amylin Pharmaceuticals Inc	Exendin 3 and 4 agonist compounds for the treatment of diabetes
EP1950224A3 (fr)	1998-03-09	2008-12-17	Zealand Pharma A/S	Conjugués peptides pharmacologiquement actifs dotés d'une tendance réduite à l'hydrolyse enzymatique
SG125915A1 (en)	1998-12-07	2006-10-30	Sod Conseils Rech Applic	Analogues of glp-1
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
HUP0200297A3 (en)	1999-03-17	2002-09-30	Novo Nordisk As	Method for acylating peptides and the glutaminic acid derivatives as acylating agents
EP1076066A1 (fr)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides abaissant le taux de glucose sanguin
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
AU2002346491A1 (en)	2001-12-19	2003-07-09	Eli Lilly And Company	Crystalline compositions for controlling blood glucose
EP1545460A4 (fr)	2001-12-20	2005-11-16	Lilly Co Eli	Molecule d'insuline a duree d'action prolongee
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
CA2518776A1 (fr)	2003-04-29	2004-11-11	Eli Lilly And Company	Analogues de l'insuline ayant une action prolongee
WO2006134340A2 (fr)	2005-06-13	2006-12-21	Imperial Innovations Limited	Nouveaux composes et leurs effets sur le comportement alimentaire
US20090202497A1 (en)	2005-08-23	2009-08-13	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
WO2007056362A2 (fr) *	2005-11-07	2007-05-18	Indiana University Research And Technology Corporation	Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
WO2007081824A2 (fr)	2006-01-06	2007-07-19	Case Western Reserve University	Protéines résistantes à la fibrillation
AU2007221366B2 (en)	2006-02-22	2012-08-23	Msd Italia S.R.L.	Oxyntomodulin derivatives
CN101622276B (zh)	2006-07-18	2015-04-22	赛诺菲-安万特	用于治疗癌症的抗epha2的拮抗抗体
WO2008043033A2 (fr)	2006-10-04	2008-04-10	Case Western Reserve University	Insuline et analogues de l'insuline résistants à la fibrillation
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
EA017849B1 (ru)	2007-02-15	2013-03-29	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Соагонисты глюкагоновых/glp-1-рецепторов
WO2008152403A1 (fr)	2007-06-15	2008-12-18	Zealand Pharma A/S	Analogues du glucagon
EP2025684A1 (fr)	2007-08-15	2009-02-18	Zealand Pharma A/S	Analogues du glucagon
KR101656107B1 (ko)	2007-11-20	2016-09-08	암브룩스, 인코포레이티드	변형된 인슐린 폴리펩티드 및 이의 용도
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
AU2009203809B2 (en)	2008-01-09	2013-07-25	Sanofi-Aventis Deutschland Gmbh	Novel insulin derivatives having an extremely delayed time-action profile
CN101970476B (zh)	2008-01-09	2014-08-27	塞诺菲-安万特德国有限公司	具有超延迟时效特征的胰岛素衍生物
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009129250A2 (fr)	2008-04-14	2009-10-22	Case Western Reserve University	Analogues de l'insuline à prendre au moment des repas de stabilité améliorée
NZ588857A (en)	2008-04-22	2012-07-27	Univ Case Western Reserve	Isoform-specific insulin analogue for control blood sugar levels
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
PA8830501A1 (es)	2008-06-17	2010-07-27	Univ Indiana Res & Tech Corp	Co-agonistas del receptor de glucagon/glp-1
US8450270B2 (en)	2008-06-17	2013-05-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
PL219335B1 (pl)	2008-07-04	2015-04-30	Inst Biotechnologii I Antybiotyków	Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
MX2011001181A (es)	2008-07-31	2011-04-05	Univ Case Western Reserve	Insulina estabilizada con halogeno.
JP5635530B2 (ja)	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
ES2439499T3 (es)	2008-12-15	2014-01-23	Zealand Pharma A/S	Análogos de glucagón
US8680049B2 (en)	2008-12-15	2014-03-25	Zealand Pharma A/S	Glucagon analogues
AU2009335715B2 (en)	2008-12-19	2016-09-15	Indiana University Research And Technology Corporation	Amide-based insulin prodrugs
US8481485B2 (en)	2008-12-19	2013-07-09	Indiana University Research And Technology Corporation	Insulin analogs
CN101519446A (zh)	2009-03-31	2009-09-02	上海一就生物医药有限公司	一种重组人胰岛素及其类似物的制备方法
PT2454282E (pt)	2009-07-13	2015-06-23	Zealand Pharma As	Análogos de glucagão acilados
BR112012018104A2 (pt)	2010-01-20	2017-10-17	Zeland Pharma As	tratamento de doenças cardíacas
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
MA34383B1 (fr)	2010-06-24	2013-07-03	Zealand Pharma As	Analogues de glucagon
MX2013008005A (es)	2011-01-20	2013-08-21	Zealand Pharma As	Combinacion de analogos de glucagon acilados con analogos de insulina.

2008
- 2008-12-15 KR KR1020157027018A patent/KR20150116912A/ko not_active Ceased
- 2008-12-15 SG SG2011043700A patent/SG172170A1/en unknown
- 2008-12-15 US US13/139,493 patent/US8685919B2/en not_active Expired - Fee Related
- 2008-12-15 AP AP2011005774A patent/AP2011005774A0/xx unknown
- 2008-12-15 WO PCT/GB2008/004121 patent/WO2010070251A1/fr not_active Ceased
- 2008-12-15 MY MYPI2011002751A patent/MY160219A/en unknown
- 2008-12-15 CN CN200880132682.4A patent/CN102282167B/zh not_active Expired - Fee Related
- 2008-12-15 MX MX2011006313A patent/MX2011006313A/es active IP Right Grant
- 2008-12-15 JP JP2011540187A patent/JP5635529B2/ja not_active Expired - Fee Related
- 2008-12-15 CA CA2747109A patent/CA2747109A1/fr not_active Abandoned
- 2008-12-15 KR KR1020117016184A patent/KR20110126589A/ko not_active Ceased
- 2008-12-15 BR BRPI0823378A patent/BRPI0823378A2/pt not_active IP Right Cessation
- 2008-12-15 EP EP14175826.8A patent/EP2799447B1/fr active Active
- 2008-12-15 MA MA34020A patent/MA32970B1/fr unknown
- 2008-12-15 EP EP08875670A patent/EP2370459A1/fr not_active Withdrawn
- 2008-12-15 AU AU2008365555A patent/AU2008365555B2/en not_active Ceased
- 2008-12-15 UA UAA201108817A patent/UA104605C2/uk unknown
- 2008-12-15 EA EA201190047A patent/EA020537B1/ru not_active IP Right Cessation
2011
- 2011-06-10 TN TN2011000295A patent/TN2011000295A1/fr unknown
- 2011-06-12 IL IL213477A patent/IL213477A0/en unknown
2014
- 2014-03-03 US US14/195,533 patent/US20150080295A1/en not_active Abandoned
2015
- 2015-05-05 HK HK15104289.5A patent/HK1203531A1/en unknown

Also Published As

Publication number	Publication date
SG172170A1 (en)	2011-07-28
JP2012511899A (ja)	2012-05-31
CN102282167A (zh)	2011-12-14
CA2747109A1 (fr)	2010-06-24
AU2008365555B2 (en)	2016-01-14
HK1203531A1 (en)	2015-10-30
MY160219A (en)	2017-02-28
AU2008365555A1 (en)	2011-07-21
MX2011006313A (es)	2011-09-27
EA020537B1 (ru)	2014-11-28
KR20150116912A (ko)	2015-10-16
TN2011000295A1 (en)	2012-12-17
EP2799447B1 (fr)	2016-11-23
EA201190047A1 (ru)	2012-02-28
EP2370459A1 (fr)	2011-10-05
EP2799447A3 (fr)	2014-12-31
US8685919B2 (en)	2014-04-01
JP5635529B2 (ja)	2014-12-03
US20110286982A1 (en)	2011-11-24
EP2799447A2 (fr)	2014-11-05
US20150080295A1 (en)	2015-03-19
IL213477A0 (en)	2011-07-31
MA32970B1 (fr)	2012-01-02
KR20110126589A (ko)	2011-11-23
CN102282167B (zh)	2014-08-13
UA104605C2 (uk)	2014-02-25
BRPI0823378A2 (pt)	2019-09-24
WO2010070251A1 (fr)	2010-06-24

Publication	Publication Date	Title
AP2011005774A0 (en)	2011-06-30	Glucagon analogues.
IL213479A0 (en)	2011-07-31	Glucagon analogues
ZA201104593B (en)	2015-01-28	Glucagon analogues
IL213480A0 (en)	2011-07-31	Glucagon analogues
AP2012006107A0 (en)	2012-02-29	Acylated glucagon analogues.
AP2011005706A0 (en)	2011-06-30	New compounds.
AP2011005535A0 (en)	2011-02-28	Drilling platform.
PT2799428T (pt)	2017-02-17	Antagonistas de glicagina
AP2011005750A0 (en)	2011-06-30	Continuous mining.
AP2011005894A0 (en)	2011-10-31	5-alkynyl-pyridines.
GB0705547D0 (en)	2007-05-02	Distributed operation
AP2011005932A0 (en)	2011-10-31	Pyrazinoisoquinoline Compounds.
AP2011005789A0 (en)	2011-08-31	Sulfamoyl-phenyl-ureido benzamidine-derivatives asantimalarial agents.
AP2011005899A0 (en)	2011-10-31	Plaswall.
GB0711673D0 (en)	2007-07-25	Glucagon analogues
HK1158214A (en)	2012-07-13	Glucagon analogues
GB0808831D0 (en)	2008-06-18	.
GB0811138D0 (en)	2008-07-23	.
GB0801773D0 (en)	2008-03-05	I.f.d.d
GB0808387D0 (en)	2008-06-18	Glp-1
IL188627A0 (en)	2008-11-03	Classified-lahaim.com
AU2009159V (en)	2009-08-28	DB-3W5N Brachychiton Brachychiton bidwilli x (b. garawayae x b. grandiflorus)
GB0701036D0 (en)	2007-02-28	.
GB0701035D0 (en)	2007-02-28	.
GB0820576D0 (en)	2008-12-17	The stikpik project